[1] HUANG SH, LIU H.Research progress on drug treatment of pregnancy complicated with rheumatoid arthritis[J]. Maternal and Child Health Care of China(中国妇幼保健), 2017, 32(9): 2041-2044. [2] YANG L, LIU RH, HUANG SB.Research progress on pathogenesis and therapeutic drugs of rheumatoid arthritis[J]. China Pharmacy(中国药房), 2021, 32(17): 2154-2159. [3] ZHANG YM, ZHAO J, GAO QH.Investigation of adalimumab on quality of life in 302 patients with moderate to severe rheumatoid arthritis[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2015, 12(2): 120-123. [4] ZHAO XY, BAI N.The therapeutic effect of combination methotrexate with adlimumab in rheumatoid arthritis[J]. Chinese Journal of Difficult and Complicated Cases(疑难病杂志), 2014(4): 381-384. [5] KWAK B, MULHAUPT F, VEILLARD N, et al.The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells[J]. Swiss Medical Weekly, 2001, 131(3-4): 41-46. [6] YANG CH, HUANG F.Application of infliximab in rheumatic diseases[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2006, 3(6): 5-10. [7] ZONG X,WANG YL.On OpenFDA and enlightenments for data management of Food and Drug Administration in China[J]. Chinese Pharmaceutical Affairs(中国药事), 2017, 31(9):976-979. [8] BO QY, XIONG NN, ZOU JD.Internationally agreed medical terminology: medical dictionary for regulatory activities[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2007, 12(5): 586-590. [9] WANG YM, MENG L, LIU X.ADR signal mining of paclitaxel for injection(Albumin- bound type)based on fda adverse event databas[J]. China Pharmacy(中国药房), 2021, 32(3): 328-333. [10] HOU YF, LIU CL, SONG HB.Optimized signal detection model in adverse drug reaction monitoring system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(7): 408-409, 421. [11] LI YY, ZHANG Y, SHEN AZ.Research progress of adverse drug reaction signal detection methods based on spontaneous reporting system[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2015, 19(7): 1233-1236. [12] HE L, LIU Y, CHENG NN, SONG HB.An improved algorithm for ADR signal detection and its application to Shanghai spontaneous ADR reporting system[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2008, 17(6): 348-352. [13] HOFF M, KVIEN TK, KLVESTEN J, et al.Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study[J]. BMC Musculoskeletal Disorders, 2011, 12(54): 54. [14] CHEN YC, LI N.Peripheral patent - patent defense weapon of adalimumab (Humira®)[J]. China Science And Technology Information(中国科技信息), 2021(14): 31-33. [15] LISA, URQUHART. Top drugs and companies by sales in2018[J]. Nature Reviews. Drug Discovery, 2019(18): 245. [16] LI JF, HU Y, PANG HX.Comparative analysis of the adverse drug rea-ctions of evolocumab and alirocumab based on OpenFDA[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(10): 4. [17] ZHOU DM, LIU CM, WEI J.Structural analysis of hospitalized patients with rheumatoid arthritis[J]. The Journal of Medical Theory and Practice(医学理论与实践), 2021, 34(17): 3095-3097. [18] CHEN J, CHENG H, LI YL.Literature analysis of rituximab related progressive multifocal leukoencephalopathy[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2022, 19(1): 39-42. [19] FOCOSI D, TUCCORI M, MAGGI F, et al.Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab[J]. Rev Med Virol, 2019, 29(6): e2077. [20] COLLAMER AN, BATTAFARANO DF.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immu-nopathogenesis[J].Semin Arthritis Rheum, 2010,40(3) : 233-240. [21] YU P, SHI HJ, YUAN W.A case of psoriasis caused by adalimumab[J]. Chinese Journal of Rheumatology(中华风湿病学杂志), 2021, 25(10): 686-687. [22] WANG L, YAO HW.Systematic evaluation of the efficacy and safety of adalimumab in the treatment of rheumatoid arthritis[J]. Shanxi Medical Journal(山西医药杂志), 2021, 50(15): 3. |